(PharmaNewsWire.Com, June 12, 2020 ) The major factors driving the growth of the Leukapheresis Market include the rising incidence and prevalence of leukemia, growing demand for leukopaks, and the increasing number of blood donations. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes.
The Leukapheresis Products Market is expected to reach USD 27.7 million, at a CAGR of 7.4%
The Leukopaks Market is expected to reach USD 445.6 million, at a CAGR of 46.4% during the forecast period.
Leukapheresis Market Major Drivers;
Increasing incidence and prevalence of leukemia;
Globally, the incidence of leukemia has risen significantly. According to the NIH National Cancer Institute in 2015, 405,815 people were suffering from leukemia in the US. According to NIH estimates, the number of new cases of leukemia has increased on an average rate of 0.3% each year over the last 10 years (from 2006 to 2015). The NIH also estimates that the number of new cases may reach 60,300 in 2018. According to the Leukemia & Lymphoma Society, from 2010 to 2014, leukemia was the sixth-most-common cause of cancer deaths globally.
By product, the apheresis devices segment is expected to account for the largest share of the leukapheresis devices market in 2018
On the basis of type, the leukapheresis devices market is segmented into apheresis devices, leukapheresis columns & cell separators, and leukoreduction filters. In 2017, the apheresis devices segment accounted for the largest share of the leukapheresis devices market. The large share of this segment is attributed to the widespread adoption of apheresis devices for performing therapeutic leukapheresis procedures for the treatment of leukemia and development of leukopaks for clinical and preclinical research.
By product, the mobilized PB leukopaks segment is expected to account for the largest share of the leukopaks market in 2018
On the basis of type, the leuopaks market is segmented into mobilized PB leukopaks, non-mobilized PB leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized PB leukopaks segment is expected to account for the largest share of the global leukopaks market in 2018. The dominant share of this segment is attributed to the increasing demand for low-granulocyte and low-hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.
Asia Pacific is expected to account for the largest share of the leukapheresis market in 2018, followed by North America. The increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the presence of leading pharma and biotech companies focusing on cell therapy research are factors are driving the growth of this regional segment.
The prominent players in the global leukapheresis products market are Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics Corporation (US), Terumo BCT (US), STEMCELL Technologies (Canada), and Macopharma (France).
Some prominent players in the leukopaks market are HemaCare (US), AllCells (US), StemExpress (US), PPA Research Group (US), Key Biologics (US), Caltag Medsystem (UK), ZenBio (US), Precision for Medicine (US), and BioIVT (US).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
